ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.

老虎证券2026/03/26 11:56

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Diageo (DEO.US) Q1 organic sales unexpectedly rose 1.4%: North America declined 3.6%, becoming a drag, while the full-year flat guidance remains unchanged.

Diageo's first-quarter organic net sales unexpectedly rose by 1.4% to $4.93 billion, with Latin America and Asia Pacific leading the growth, while North America still declined by 3.6%. The company maintains its guidance of flat performance for the full year.

智通财经•2026/11/05 07:57

Deutsche Bank raises EchoStar Communications target price to $134

格隆汇•2026/11/05 07:45

Updated version 3 - Toyota profits surge and annual forecast raised, hybrid vehicle sales strong

路透社•2026/11/05 07:36

A net loss of approximately $555,000 has occurred due to the TENDRIL sell mechanism vulnerability.

Odaily星球日报•2026/11/05 07:31